BIO-TECHNE Corp 8-K, filed Dec 22, 2021
BIO-TECHNE Corp (TECH)
About this 8-K
BIO-TECHNE Corp filed this 8-K on December 22, 2021, reporting on events of December 20, 2021.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification
Number)
|
|
|
||
|
(Address of Principal Executive Offices) (Zip Code)
|
||
|
(
|
||
|
(Registrant’s Telephone Number, Including Area Code)
|
||
|
Not Applicable
|
||
|
(Former Name or Former Address, if Changed Since Last Report)
|
||
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Emerging growth company
|
|
●
|
Base salary of $500,000;
|
|
●
|
Participation in the Management Incentive Plan, with a cash bonus of 85% at target and annual equity grants with both time- and performance-based vesting, valued at approximately $1.8 million, with a pro-rated grant of such equity to be issued February 1, 2022;
|
|
●
|
A one-time grant of restricted stock units valued at $1 million, to be issued February 1, 2022, with vesting of one third each on the three anniversaries following the date of grant;
|
|
●
|
Reimbursement of certain business expenses in connection with his service to the Company, relocation allowance and participation in other employee benefit plans generally available to the Company’s employees, and certain other benefits as set forth in the Employment Agreement.
|
|
|
(d) Exhibits
|
|
99.1
|
|
104 -
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
BIO-TECHNE CORPORATION
|
|||
|
Date: December 21, 2021
|
By:
|
/s/ Brenda S. Furlow
|
|
|
Brenda S. Furlow
|
|||
|
Executive Vice President, General Counsel and Secretary
|
|||
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release, dated December 21, 2021
|
|
|
104 -
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Exhibit. 99.1
BIO-TECHNE ANNOUNCES APPOINTMENT OF WILL GEIST AS PRESIDENT, PROTEIN SCIENCES SEGMENT
Minneapolis/December 21, 2021/ Bio-Techne Corporation (NASDAQ: TECH) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3, 2022. Mr. Geist succeeds N. David Eansor, who will be retiring from the Company. Mr. Eansor will remain with Bio-Techne through the end of February 2022 to ensure a smooth transition.
Mr. Geist has over two decades of experience as a senior life science tools leader, most recently serving as Chief Operating Officer for Quanterix, where he was responsible for enterprise-wide operations and strategy deployment. Previously Mr. Geist was Vice President & General Manager for two of Thermo Fisher Scientific’s largest Business Units, Protein & Cell Analysis and qPCR. Prior to Thermo Fisher Scientific, Mr. Geist was Vice President of QuantaBiosciences, a QIAGEN company, where he held various roles of increasing responsibility from the company’s inception through its acquisition.
“I want to personally thank Dave for his leadership and significant contributions over the last seven years at Bio-Techne. He has played an integral role in the Company’s success, and I wish him the best in his retirement,” said Chuck Kummeth, President and Chief Executive of Bio-Techne. “Will is joining Bio-Techne at a very exciting point in the Company’s growth trajectory. His experience running life science tools businesses generating over $1 billion in annual revenue make him the ideal candidate to take the Protein Sciences Segment through its next phase of growth.”
About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416